JP2001523221A - 親油性物質の促進された生物学的利用能のための固形共沈物 - Google Patents

親油性物質の促進された生物学的利用能のための固形共沈物

Info

Publication number
JP2001523221A
JP2001523221A JP51187998A JP51187998A JP2001523221A JP 2001523221 A JP2001523221 A JP 2001523221A JP 51187998 A JP51187998 A JP 51187998A JP 51187998 A JP51187998 A JP 51187998A JP 2001523221 A JP2001523221 A JP 2001523221A
Authority
JP
Japan
Prior art keywords
composition
tpgs
coprecipitate
solid
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51187998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523221A5 (enExample
Inventor
シモン アムセレム
Original Assignee
ファーモス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11917696A external-priority patent/IL119176A/en
Priority claimed from US08/833,076 external-priority patent/US5891469A/en
Application filed by ファーモス コーポレイション filed Critical ファーモス コーポレイション
Publication of JP2001523221A publication Critical patent/JP2001523221A/ja
Publication of JP2001523221A5 publication Critical patent/JP2001523221A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP51187998A 1996-09-01 1997-08-27 親油性物質の促進された生物学的利用能のための固形共沈物 Ceased JP2001523221A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL11917696A IL119176A (en) 1996-09-01 1996-09-01 Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
US08/833,076 1997-04-02
US08/833,076 US5891469A (en) 1997-04-02 1997-04-02 Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US119176 1997-04-02
PCT/US1997/015072 WO1998008490A1 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Publications (2)

Publication Number Publication Date
JP2001523221A true JP2001523221A (ja) 2001-11-20
JP2001523221A5 JP2001523221A5 (enExample) 2005-05-12

Family

ID=26323300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51187998A Ceased JP2001523221A (ja) 1996-09-01 1997-08-27 親油性物質の促進された生物学的利用能のための固形共沈物

Country Status (5)

Country Link
EP (1) EP1017366A4 (enExample)
JP (1) JP2001523221A (enExample)
AU (1) AU730216B2 (enExample)
CA (1) CA2264718C (enExample)
WO (1) WO1998008490A1 (enExample)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531652A (ja) * 2002-06-07 2005-10-20 フラメル・テクノロジー α−トコフェロールを用いて機能化されたポリアミノ酸、およびその使用、特に治療学的使用
JP2006517929A (ja) * 2003-02-19 2006-08-03 ハー・ルンドベック・アクチエゼルスカベット 溶融アグロメレーションを用いてアグロメレートを製造する方法
JP2007510658A (ja) * 2003-11-03 2007-04-26 リポシン， インコーポレイテッド 可溶化剤放出が同調する薬学的組成物
JP2008514607A (ja) * 2004-09-24 2008-05-08 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 新規な種類の界面活性剤様物質
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP2010150264A (ja) * 2005-12-19 2010-07-08 Ind Technol Res Inst グルタチオンベースデリバリーシステム
WO2010092925A1 (ja) * 2009-02-12 2010-08-19 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP2012516346A (ja) * 2009-01-29 2012-07-19 ノバルティス アーゲー ピリドピリミジノンの経口用固体製剤
JP2012524092A (ja) * 2009-04-14 2012-10-11 ブリストル−マイヤーズ スクイブ カンパニー アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物
US8673863B2 (en) 2005-12-19 2014-03-18 Industrial Technology Research Institute Glutathione-based delivery system
JP2016506390A (ja) * 2012-12-06 2016-03-03 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ 選択的プロゲステロン受容体モジュレーターの固体分散体
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
JP2020503357A (ja) * 2017-01-03 2020-01-30 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤
JP2020509081A (ja) * 2017-02-15 2020-03-26 モレキュラー インフュージョンズ、エルエルシー 製剤
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
JP2023507430A (ja) * 2019-12-20 2023-02-22 イドルシア ファーマスーティカルズ リミテッド Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセトアミドを含む薬学的組成物
JP2023517749A (ja) * 2020-03-19 2023-04-26 エーシー イミューン エス．エー． タウオパチーの投薬治療
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
JP2024515676A (ja) * 2021-04-17 2024-04-10 バーミズ リサーチ ラボラトリー， プライベート リミテッド ポリペプチド製剤
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1298731B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US6632443B2 (en) * 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AU2023401A (en) * 1999-12-01 2001-06-12 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
DE60111352T2 (de) * 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin-zusammensetzungen
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006518380A (ja) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
US20070149509A1 (en) * 2003-12-18 2007-06-28 Luca Barella Use of vitamin e
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
WO2008007728A1 (fr) * 2006-07-13 2008-01-17 Kaneka Corporation Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
MX2010010050A (es) 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
EP2563164B1 (en) 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
HUP1300647A2 (hu) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
WO2016044813A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN108245683B (zh) * 2018-01-26 2020-02-14 华中科技大学 一种具有p-糖蛋白抑制功能的抗肿瘤前药及制备方法
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
KR20220119024A (ko) 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물
IT202200002528A1 (it) * 2022-02-11 2023-08-11 Pierpaoli Exelyas S R L Composizione comprendente melatonina ad alta biodisponibilità

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531652A (ja) * 2002-06-07 2005-10-20 フラメル・テクノロジー α−トコフェロールを用いて機能化されたポリアミノ酸、およびその使用、特に治療学的使用
JP2006517929A (ja) * 2003-02-19 2006-08-03 ハー・ルンドベック・アクチエゼルスカベット 溶融アグロメレーションを用いてアグロメレートを製造する方法
JP2007510658A (ja) * 2003-11-03 2007-04-26 リポシン， インコーポレイテッド 可溶化剤放出が同調する薬学的組成物
JP2008514607A (ja) * 2004-09-24 2008-05-08 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 新規な種類の界面活性剤様物質
US8673863B2 (en) 2005-12-19 2014-03-18 Industrial Technology Research Institute Glutathione-based delivery system
JP2010150264A (ja) * 2005-12-19 2010-07-08 Ind Technol Res Inst グルタチオンベースデリバリーシステム
US8722094B2 (en) 2008-03-11 2014-05-13 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP2012516346A (ja) * 2009-01-29 2012-07-19 ノバルティス アーゲー ピリドピリミジノンの経口用固体製剤
WO2010092925A1 (ja) * 2009-02-12 2010-08-19 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP2012524092A (ja) * 2009-04-14 2012-10-11 ブリストル−マイヤーズ スクイブ カンパニー アモルファスアルファ−（ｎ−スルホンアミド）アセトアミド化合物の生物学的に利用可能なカプセル組成物
JP2016506390A (ja) * 2012-12-06 2016-03-03 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ 選択的プロゲステロン受容体モジュレーターの固体分散体
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
JP2023071697A (ja) * 2017-01-03 2023-05-23 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤
JP7281815B2 (ja) 2017-01-03 2023-05-26 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤
JP7466238B2 (ja) 2017-01-03 2024-04-12 スポーク・サイエンシズ・インコーポレイテッド 医薬化合物及び栄養補給剤
JP2020503357A (ja) * 2017-01-03 2020-01-30 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤
JP2020509081A (ja) * 2017-02-15 2020-03-26 モレキュラー インフュージョンズ、エルエルシー 製剤
JP2023507430A (ja) * 2019-12-20 2023-02-22 イドルシア ファーマスーティカルズ リミテッド Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセトアミドを含む薬学的組成物
JP2023517749A (ja) * 2020-03-19 2023-04-26 エーシー イミューン エス．エー． タウオパチーの投薬治療
JP2024515676A (ja) * 2021-04-17 2024-04-10 バーミズ リサーチ ラボラトリー， プライベート リミテッド ポリペプチド製剤

Also Published As

Publication number Publication date
WO1998008490A1 (en) 1998-03-05
EP1017366A4 (en) 2006-03-22
CA2264718C (en) 2006-05-30
AU4237397A (en) 1998-03-19
AU730216B2 (en) 2001-03-01
EP1017366A1 (en) 2000-07-12
CA2264718A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
AU730216B2 (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891469A (en) Solid Coprecipitates for enhanced bioavailability of lipophilic substances
AU722217B2 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
EP1345597B1 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
EP3280398B1 (en) Self-emulsifying formulations of dim-related indoles
JP2010090132A (ja) 流動床噴霧乾燥によるナノ粒子製造方法
WO2021109823A1 (zh) 一种大麻素纳米胶束制剂及其制备方法
JPH08509475A (ja) アルコール及び疎水性薬物を含有する医薬として許容された改良組成物
JP2001505928A (ja) シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物
US20040248901A1 (en) Compositions containing itraconazole and their preparation methods
AU2002226374A1 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US20040180961A1 (en) Compositions and preparation methods for bioavailable oral aceclofenac dosage forms
Jain et al. Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement
EP3854384A1 (en) Pharmaceutical formulation comprising abiraterone acetate
MX2007007887A (es) Sistema galenico novedoso para transporte del principio activo, metodo de preparacion y uso.
CN101282716A (zh) 具有改善的初始溶解率的普仑司特固体分散体的药物组合物和制备该组合物的方法
IL119176A (en) Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
Liu et al. Inhalable disulfiram pure-drug nanoparticles stabilized by phospholipid/TPSS for effective pulmonary fibrosis treatment in mice
CA2251194C (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
KR101279568B1 (ko) 메게스트롤 아세테이트를 포함하는 경구용 약학 조성물
CN114599347B (zh) 治疗肾上腺皮质癌与库欣综合征的口服施用的包含米托坦的药物组合物
KR20040084240A (ko) 고형지질나노입자, 이를 함유하는 활성성분 전달용약학조성물 및 이의 제조방법
IL126384A (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
SI26054A (sl) Supernasičljiv brez olja samo-nanoemulgirni sistem za dovajanje zdravil - SNEDDS za v vodi slabo topne farmacevtske sestavine in postopek njegove priprave
JPWO1996019239A1 (ja) 溶解性及び吸収性が向上した固体組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040827

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20040827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080929

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324